Present and future of drug therapy in hypertension: an overview

References

• Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):1–12. doi: 10.1016/S0140-6736(12)61766-8.
   PubMed Web of Science ®Google Scholar
• Magnussen C, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. New Eng J Med. 2023;389:1273–1285.
   PubMed Web of Science ®Google Scholar
• Elsaid N, Saied A, Kandil H, et al. Impact of stress and hypertension on the cerebrovasculature. Front Biosci. 2021;26(12):1643–1652. doi: 10.52586/5057.
   Web of Science ®Google Scholar
• Böhm M, Schumacher H, Teo KK, et al. Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Eur Heart J. 2018;39(33):3105–3114. doi: 10.1093/eurheartj/ehy287.
   PubMed Web of Science ®Google Scholar
• Redon J, Olsen MH, Cooper RS, et al. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and central Asia: implications for control of high blood pressure. Eur Heart J. 2011;32(11):1424–1431. doi: 10.1093/eurheartj/ehr045.
   PubMed Web of Science ®Google Scholar
• Böhm M, Schumacher H, Teo KK, et al. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J Hypertens. 2021;39(4):766–774. doi: 10.1097/HJH.0000000000002697.
   PubMed Web of Science ®Google Scholar
• De Anda-Duran I, Woltz SG, Bell CN, et al. Hypertension and cognitive function: a review of life-course factors and disparities. Curr Opin Cardiol. 2022;37(4):326–333. doi: 10.1097/HCO.0000000000000975.
   PubMed Web of Science ®Google Scholar
• Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980. doi: 10.1016/S0140-6736(21)01330-1.
   PubMed Web of Science ®Google Scholar
• Redon J, Mourad JJ, Schmieder RE, et al. Why in 2016 are patients with hypertension not 100% controlled? A call to action. J Hypertens. 2016;34(8):1480–1488. doi: 10.1097/HJH.0000000000000988.
   PubMed Web of Science ®Google Scholar
• Bentham J, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390:2627–2642.
   PubMed Web of Science ®Google Scholar
• Mancia G, Kjeldsen SE, Kreutz R, et al. Individualized Beta-Blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 european society of cardiology/european society of hypertension guidelines. Hypertension. 2022;79(6):1153–1166. doi: 10.1161/HYPERTENSIONAHA.122.19020.
   PubMed Web of Science ®Google Scholar
• Thomopoulos C, Bazoukis G, Tsioufis C, et al. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. J Hypertens. 2020;38(9):1669–1681. doi: 10.1097/HJH.0000000000002523.
   PubMed Web of Science ®Google Scholar
• Redón J, Pascual-Izuel JM, Rodilla E, et al. Effects of nebivolol and atenolol on Central aortic pressure in hypertensive patients: a multicenter, randomized, double-blind study. Blood Press. 2014;23(3):181–188. doi: 10.3109/08037051.2013.840421.
   PubMed Web of Science ®Google Scholar
• Stokes GS, Marwood JF. Review of the use of alpha-adrenoceptor antagonists in hypertension. Methods Find Exp Clin Pharmacol. 1984;6(4):197–204.
   PubMedGoogle Scholar
• Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341(19):1447–1457. doi: 10.1056/NEJM199911043411907.
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Ram CVS. Calcium channel blockers. J Clin Hypertens. 2011;13(9):687–689. doi: 10.1111/j.1751-7176.2011.00513.x.
   PubMed Web of Science ®Google Scholar
• Sica DA, Carter B, Cushman W, et al. Thiazide and loop diuretics. J Clin Hypertens. 2011;13(9):639–643. doi: 10.1111/j.1751-7176.2011.00512.x.
   PubMed Web of Science ®Google Scholar
• Ishani A, Cushman WC, Leatherman SM, et al. Chlorthalidone vs. Hydrochlorothiazide for hypertension–cardiovascular events. N Engl J Med. 2022;387(26):2401–2410. doi: 10.1056/NEJMoa2212270.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385(27):2507–2519. doi: 10.1056/NEJMoa2110730.
   PubMed Web of Science ®Google Scholar
• Lewis E, Hunsicker L, Bain R, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. Cardiovasc Rev Rep. 1994;15:69.
   Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the Angiotensin-Receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860. doi: 10.1056/NEJMoa011303.
   PubMed Web of Science ®Google Scholar
• Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354(2):131–140. doi: 10.1056/NEJMoa053107.
   PubMed Web of Science ®Google Scholar
• Redon J, Mancia G, Sleight P, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing telmisartan alone and in combination with ramipril global endpoint trial). J Am Coll Cardiol. 2012;59(1):74–83. doi: 10.1016/j.jacc.2011.09.040.
   PubMed Web of Science ®Google Scholar
• Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol. 2008;51(5):519–528. doi: 10.1016/j.jacc.2007.10.027.
   PubMed Web of Science ®Google Scholar
• Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–788.
   PubMed Web of Science ®Google Scholar
• Deng Z, Jiang J, Wang J, et al. Angiotensin receptor blockers are associated with a lower risk of progression from mild cognitive impairment to dementia. Hypertension. 2022;79(10):2159–2169. doi: 10.1161/HYPERTENSIONAHA.122.19378.
   PubMed Web of Science ®Google Scholar
• Paczkowska‐walendowska M, Sip S, Staszewski R, et al. Single-Pill combination to improve hypertension treatment: pharmaceutical industry development. Int J Environ Res Public Health. 2022;19(7):4156. doi: 10.3390/ijerph19074156.
   PubMed Web of Science ®Google Scholar
• Parati G, Kjeldsen S, Coca A, et al. Adherence to Single-Pill versus Free-Equivalent combination therapy in hypertension: a systematic review and Meta-Analysis. Hypertension. 2021;77(2):692–705. doi: 10.1161/HYPERTENSIONAHA.120.15781.
   PubMed Web of Science ®Google Scholar
• Mancia G, Kreutz R, Brunström M, et al. ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the european society of hypertension: endorsed by the international society of hypertension (ISH) and the european renal association (ERA). J Hypertens. 2023;41(12):1874–2071. doi: 10.1097/HJH.0000000000003480.
   PubMed Web of Science ®Google Scholar
• Docherty KF, Vaduganathan M, Solomon SD, et al. Sacubitril/valsartan: neprilysin inhibition 5 years after PARADIGM-HF. JACC Heart Fail. 2020;8(10):800–810. doi: 10.1016/j.jchf.2020.06.020.
   PubMed Web of Science ®Google Scholar
• Jackson AM, Jhund PS, Anand IS, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021;42(36):3741–3752. doi: 10.1093/eurheartj/ehab499.
   PubMed Web of Science ®Google Scholar
• Williams B, Cockcroft JR, Kario K, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension. Hypertension. 2017;69(3):411–420. doi: 10.1161/HYPERTENSIONAHA.116.08556.
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for industry on diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes; Availability. 2008. https://www.federalregister.gov/documents/2008/12/19/E8-30086/guidance-for-industry-on-diabetes-mellitus-evaluating-cardiovascular-risk-in-new-antidiabetic
   Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. doi: 10.1093/eurheartj/ehz486.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15–30. doi: 10.1016/j.cmet.2016.06.009.
   PubMed Web of Science ®Google Scholar
• Liakos CI, Papadopoulos DP, Sanidas EA, et al. Blood Pressure-Lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors). Am J Cardiovasc Drugs. 2021;21(2):123–137. doi: 10.1007/s40256-020-00423-z.
   PubMed Web of Science ®Google Scholar
• Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med. 2022;386(21):2024–2034. doi: 10.1056/NEJMra2115011.
   PubMed Web of Science ®Google Scholar
• Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens. 2015;9(1):48–53. doi: 10.1016/j.jash.2014.11.001.
   PubMed Web of Science ®Google Scholar
• Sanidas EA, Papadopoulos DP, Hatziagelaki E, et al. Sodium glucose cotransporter 2 (SGLT2) inhibitors across the spectrum of hypertension. Am J Hypertens. 2020;33(3):207–213. doi: 10.1093/ajh/hpz157.
   PubMed Web of Science ®Google Scholar
• Mancia G, Cannon CP, Tikkanen I, et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension. 2016;68(6):1355–1364. doi: 10.1161/HYPERTENSION­AHA.116.07703.
   PubMed Web of Science ®Google Scholar
• Mazidi M, Rezaie P, Gao HK, et al. Effect of Sodium-Glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6(6):e004007. doi: 10.1161/JAHA.116.004007.
   PubMed Web of Science ®Google Scholar
• Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care. 2019;42(4):693–700. doi: 10.2337/dc18-2207.
   PubMed Web of Science ®Google Scholar
• Posch MG, Walther N, Ferrannini E, et al. Metabolic, intestinal, and cardiovascular effects of sotagliflozin compared with empagliflozin in patients with type 2 diabetes: a randomized, double-blind study. Diabetes Care. 2022;45(9):2118–2126. doi: 10.2337/dc21-2166.
   PubMed Web of Science ®Google Scholar
• Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators. N Engl J Med. 1998;338(12):784–790. doi: 10.1056/NEJM199803193381202.
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927–1937. doi: 10.1016/S0140-6736(22)02034-7.
   PubMed Web of Science ®Google Scholar
• Blazek O, Bakris GL. Novel therapies on the horizon of hypertension management. Am J Hypertens. 2023;36(2):73–81. doi: 10.1093/ajh/hpac111.
   PubMed Web of Science ®Google Scholar
• Fournie-Zaluski M-C, Fassot C, Valentin B, et al. Brain renin-angiotensin system blockade by systemically active aminopeptidase a inhibitors: a potential treatment of salt-dependent hypertension. Proc Natl Acad Sci U S A. 2004;101(20):7775–7780. doi: 10.1073/pnas.0402312101.
   PubMed Web of Science ®Google Scholar
• Bodineau L, Frugière A, Marc Y, et al. Orally active aminopeptidase a inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension. 2008;51(5):1318–1325. doi: 10.1161/HYPERTENSIONAHA.107.098772.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Balavoine F, Besse B, et al. Efficacy and safety of firibastat, a first-in-class brain aminopeptidase a inhibitor, in hypertensive overweight patients of multiple ethnic origins. Circulation. 2019;140(2):138–146. doi: 10.1161/CIRCULATIONAHA.119.040070.
   PubMed Web of Science ®Google Scholar
• Schaffer R, Laffin L, Smith R. Firibastat fails to improve BP in resistant hypertension: FRESH. Cardiol Today. 2022.
   Google Scholar
• Barrera-Chimal J, Bonnard B, Jaisser F. Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases. Annu Rev Physiol. 2022;84(1):585–610. doi: 10.1146/annurev-physiol-060821-013950.
   PubMedGoogle Scholar
• Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):E53–E90. doi: 10.1161/HYP.0000000000000084.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152–161. doi: 10.1093/eurheartj/ehaa736.
   PubMed Web of Science ®Google Scholar
• Bärfacker L, Kuhl A, Hillisch A, et al. Discovery of Bay 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385–1403. doi: 10.1002/cmdc.201200081.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474–484. A doi: 10.1093/eurheartj/ehab777.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Ruilope LM, Ruiz-Hurtado G, et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023;41(2):295–302. doi: 10.1097/HJH.0000000000003330.
   PubMed Web of Science ®Google Scholar
• Ito S, Itoh H, Rakugi H, et al. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. J Hum Hypertens. 2019;33(7):542–551. doi: 10.1038/s41371-019-0207-x.
   PubMed Web of Science ®Google Scholar
• Bakris G, Pergola PE, Delgado B, et al. Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study. Hypertension. 2021;78(1):74–81. doi: 10.1161/HYPERTENSIONAHA.121.17073.
   PubMed Web of Science ®Google Scholar
• Freeman MW, Halvorsen Y-D, Marshall W, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395–405. doi: 10.1056/NEJMoa2213169.
   PubMed Web of Science ®Google Scholar
• Freeman M, Halvorsen Y, Brown M. Baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388:1820–1822.
   Google Scholar
• Grau-Perez M, Redon J. Unraveling new factors associated with hypertension: the mendelian randomization approach. J Hypertens. 2020;38(1):30–32. doi: 10.1097/HJH.0000000000002251.
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoff RM, Johnson JA. Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol. 2016;12(2):110–122. doi: 10.1038/nrneph.2015.176.
   PubMed Web of Science ®Google Scholar
• Salvi E, Wang Z, Rizzi F, et al. Genome-wide and gene-based meta-analyses identify novel loci influencing blood pressure response to hydrochlorothiazide. Hypertension. 2017;69(1):51–59. doi: 10.1161/HYPERTENSIONAHA.116.08267.
   PubMed Web of Science ®Google Scholar
• Magvanjav O, Gong Y, McDonough CW, et al. Genetic variants associated with uncontrolled blood pressure on thiazide diuretic/β-Blocker combination therapy in the PEAR (pharmacogenomic evaluation of antihypertensive responses) and INVEST (international Verapamil-SR trandolapril study). Trials. J Am Heart Assoc. 2017;6:e006522.
   PubMed Web of Science ®Google Scholar
• Türkmen D, Masoli JAH, Delgado J, et al. Calcium-channel blockers: clinical outcome associations with reported pharmacogenetics variants in 32 000 patients. Br J Clin Pharmacol. 2023;89(2):853–864. doi: 10.1111/bcp.15541.
   PubMed Web of Science ®Google Scholar
• Hussain M, Bilal A, Awan FR. Pharmacogenetic study of ACE, AGT, CYP11B1, CYP11B2 and eNOS gene variants in hypertensive patients from Faisalabad, Pakistan. J Pak Med Assoc. 2020;70(4):624–629. doi: 10.5455/JPMA.6666.
   PubMed Web of Science ®Google Scholar
• Pandey KN. Molecular and genetic aspects of guanylyl cyclase natriuretic peptide receptor-a in regulation of blood pressure and renal function. Physiol Genomics. 2018;50(11):913–928. doi: 10.1152/physiolgenomics.00083.2018.
   PubMed Web of Science ®Google Scholar
• Cruz-López EO, Ye D, Wu C, et al. Angiotensinogen suppression: a new tool to treat cardiovascular and renal disease. Hypertension. 2022;79(10):2115–2126. doi: 10.1161/HYPERTENSIONAHA.122.18731.
   PubMed Web of Science ®Google Scholar
• Olczak KJ, Taylor-Bateman V, Nicholls HL, et al. Hypertension genetics past, present and future applications. J Intern Med. 2021;290(6):1130–1152. doi: 10.1111/joim.13352.
   PubMed Web of Science ®Google Scholar
• Morgan ES, Tami Y, Hu K, et al. Antisense inhibition of angiotensinogen with IONIS-AGT-LRx: results of phase 1 and phase 2 studies. JACC Basic Transl Sci. 2021;6(6):485–496. doi: 10.1016/j.jacbts.2021.04.004.
   PubMedGoogle Scholar
• Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389(3):228–238. doi: 10.1056/NEJMoa2208391.
   PubMed Web of Science ®Google Scholar
• Ranasinghe P, Addison ML, Webb DJ. Small interfering RNA therapeutics in hypertension: a viewpoint on vasopressor and vasopressor-sparing strategies for counteracting blood pressure lowering by angiotensinogen-targeting small interfering RNA. J Am Heart Assoc. 2022;11(20):e027694. doi: 10.1161/JAHA.122.027694.
   PubMed Web of Science ®Google Scholar
• Harrison DG, Coffman TM, Wilcox CS. Pathophysiology of hypertension: the mosaic theory and beyond. Circ Res. 2021;128(7):847–863. doi: 10.1161/CIRCRESAHA.121.318082.
   PubMed Web of Science ®Google Scholar